Funding Round
Neurocess raises €12M Series A for EEG-based early Alzheimer's detection platform
Silicon Canals3/21/2026·03/21/26🌐 Europe
Summary
Amsterdam-based Neurocess closed €12M Series A led by Forbion, with Inkef Capital, HealthInc, and Amsterdam UMC Ventures. Their AI-powered EEG analysis platform detects Alzheimer's biomarkers from a routine 20-minute recording, targeting deployment in memory clinics and primary care as a low-cost screening tool alongside blood-based biomarkers.
Why it matters
EEG-based Alzheimer's screening could democratize early detection globally — unlike PET imaging ($3,000-5,000) or spinal fluid testing, a $200 EEG study is feasible in any clinic worldwide. Forbion's backing adds neurotech-specialized VC credibility.
#EEG#Alzheimers#Neurodiagnostics#AI Diagnostics#Europe
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trialAlready a member? Sign in